-
Why AstraZeneca Is Voluntarily Withdrawing Imfinzi In US For Advanced Bladder Cancer Indication
Monday, February 22, 2021 - 3:33pm | 518Read More...AstraZeneca plc (NASDAQ: AZN) announced Monday a setback related to its key immuno-oncology therapy Imfinzi. What Happened: The U.K. drugmaker said it is voluntarily withdrawing Imfinzi from the U.S. market as a treatment option for previously treated adult patients with locally advanced or...
-
AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial
Monday, October 28, 2019 - 3:13pm | 468Read More...AstraZeneca plc (NYSE: AZN) shares were advancing Monday following a clinical readout from the company. What Happened The U.K.-based pharma giant said its Phase 3 POSEIDON trial produced positive results. The study is evaluating AstraZeneca's Imfinzi — an anti-PD-L1...
-
AstraZeneca Sharply Higher Off Positive Data For Imfinzi
Friday, May 12, 2017 - 10:29am | 100Read More...AstraZeneca plc (ADR) (NYSE: AZN) shares are trading higher by $2.33 (8 percent) at $33.45 in Friday's session. The catalyst for the rally is the announcement that its drug, Imfinzi, has met primary endpoint for the treatment of lung cancer. After a much higher open, AstraZeneca had only a 3-...
